Raymond James Financial
SPRY icon

Raymond James Financial’s ARS Pharmaceuticals SPRY Stock Holding History

Raymond James Financial’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.22M Sell
525,224
-40,832
-7% -$391K ﹤0.01% 2734
2025
Q4 		$6.59M Sell
566,056
-190,291
-25% -$1.85M ﹤0.01% 2289
2025
Q3 		$7.6M Buy
756,347
+82,977
+12% +$1.19M ﹤0.01% 2139
2025
Q2 		$11.8M Sell
673,370
-33,417
-5% -$482K ﹤0.01% 1744
2025
Q1 		$8.89M Buy
706,787
+83,506
+13% +$1M ﹤0.01% 1905
2024
Q4 		$6.58M Buy
+623,281
New +$8.73M ﹤0.01% 2146

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Raymond James Financial's SPRY Position: Q1 2026 in Review

Raymond James Financial reduced its ARS Pharmaceuticals (SPRY) stake by 7.2% in Q1 2026, selling an estimated $391K and leaving 525,224 shares worth $4.22M. The position accounts for ﹤0.01% of the portfolio, ranked #2734.

Raymond James Financial first reported a position in SPRY in Q4 2024 and has held it in 6 quarters since. The position peaked at $11.8M in Q2 2025. 203 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Raymond James Financial held 525,224 shares of ARS Pharmaceuticals worth $4.22M as of Q1 2026.
  • Raymond James Financial sold 40,832 ARS Pharmaceuticals shares in Q1 2026, an estimated $391K.
  • ARS Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #2734 holding.
  • Raymond James Financial first reported a position in ARS Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Raymond James Financial's ARS Pharmaceuticals position peaked at $11.8M in Q2 2025.
  • 203 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.